Key Developments For Immucor, Inc.
Immucor, Inc. (BLUD.O) (Nasdaq)
The Pomerantz Firm Charges Immucor, Inc. With Securities Fraud
Pomerantz Haudek Grossman & Gross LLP announced that it has filed a class action lawsuit in the United States District Court, Northern District of Georgia, against Immucor, Inc. and certain of its top officials. The class action (09-CV-2714) was filed on behalf of purchasers of the securities of the Company between October 19, 2005, and April 23, 2009 inclusive, (Class Period). The Complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5 promulgated thereunder.
Immucor, Inc. Reaffirms FY 2010 Guidance
Immucor, Inc. reaffirmed fiscal 2010 guidance for consolidated revenue to be in the range of $322-$332 million and diluted earnings per share (EPS) to be in the range of $1.10-$1.17, which includes the approximately $0.04 per share impact, net of tax, related to the Quality Process Improvement Project. According to Reuters Estimates, analysts on an average are expecting the Company to report EPS of $1.11 on revenue of $327 million for the same period.
Shareholder Class Action Filed Against Immucor, Inc. By Law Firm Of Barroway Topaz Kessler Meltzer & Check, LLP
Topaz Kessler Meltzer & Check, LLP announced that a class action lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of securities of Immucor, Inc. between October 19, 2005 and April 23, 2009 inclusive. The Complaint charges Immucor and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Immucor, together with its subsidiaries, engages in the development, manufacture, and sale of various blood reagents. More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that the Company had engaged in unlawful business practices with its competitors in the blood reagents industry; (2) that the Company had agreed with its competitors in the industry to fix, raise, maintain and stabilize prices for blood reagents and related medical equipment in the U.S. market; (3) that the Company's revenues had been significantly increased through the employment of such unlawful business practices; (4) that, as a result, the Company's financial statements were false and misleading at all relevant times; (5) that such unlawful business practices, when they were discovered, would initiate an investigation by the federal authorities into the Company's business practices; (6) that the Company lacked adequate internal and financial controls.
Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Against Immucor, Inc.
Bronstein, Gewirtz & Grossman, LLC announced that a class action has been filed in the United States District Court for the Northern District of Georgia on behalf of those who purchased or otherwise acquired stock of Immucor, Inc., during the period from October 19, 2005 through and including April 23, 2009 (the Class Period). The Complaint charges that defendant violated the Securities and Exchange Act of 1934 by failing to disclose that the Company was operating in violation of the federal antitrust laws of the United States. Immucor issued a press release on April 24, 2009, announcing that it had received a subpoena from the United States Department of Justice, Antitrust Division, pertaining to an investigation of possible violation of the federal criminal antitrust laws in the blood reagents industry.
Levi & Korsinsky, LLP Announces Class Action Lawsuit Against Immucor, Inc
Levi & Korsinsky announced that a class action lawsuit has been filed in United States District Court for the Northern District of Georgia on behalf of purchasers of Immucor, Inc. stock during the period between October 19, 2005, through April 23, 2009. The complaint alleges that Immucor and certain of its officers and directors violated the Securities Exchange Act of 1934 by failing to disclose that Immucor was operating in violation of the federal antitrust laws of the United States. On April 24, 2009, Immucor issued a press release announcing, in part, that it had received a subpoena from the United States Department of Justice, Antitrust Division, pertaining to an investigation of possible violations of the federal criminal antitrust laws in the blood reagents industry.
